Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322149 · ClinicalTrials.gov registry record · Phase 2
Multiple Doses of AT-1501-A201 in Adults With ALS
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Anelixis Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 13
- Study locations
NCT04322149 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Anelixis Therapeutics. The registered enrollment target is 54 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (94% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT04322149, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Anelixis Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.
Conditions Studied
Interventions
- DRUG AT-1501
Study Locations (13)
California
- University of California Irvine - Orange
- California Pacific Medical Center - San Francisco
Texas
- Texas Neurology, P.A. - Dallas
- Houston Methodist Neurological Institute - Houston
Arizona
- Barrows Neurological Institute - Phoenix
Georgia
- Augusta University - Augusta
Indiana
- University of Indiana - Indianapolis
Kansas
- The University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins University Medical Center - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-10-16 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322149
The ClinicalTrials.gov registry entry for NCT04322149 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (94% lower). The listed sponsor is Anelixis Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which AT-1501 is the first listed.
NCT04322149 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT04322149 about?
NCT04322149 is a clinical study titled "Multiple Doses of AT-1501-A201 in Adults With ALS". This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS tr...
What is the current status of trial NCT04322149?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-10-16. Estimated completion is 2022-03-24.
What conditions does trial NCT04322149 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT04322149?
The interventions under investigation include: AT-1501 (DRUG).
Who is sponsoring clinical trial NCT04322149?
This trial is sponsored by Anelixis Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322149 being conducted?
This trial has 13 study locations across Arizona, California, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.